Clinical Trial Detail

NCT ID NCT02973113
Title Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Baylor College of Medicine
Indications

non-Hodgkin lymphoma

Hodgkin's lymphoma

B-cell lymphoma

mature T-cell and NK-cell lymphoma

Therapies

EB-VST cells + Nivolumab

Age Groups: child adult senior

No variant requirements are available.